This content is machine translated Ozanimod for relapsing-remitting multiple sclerosis Signs of improved tolerability with prolonged treatment Ozanimod, a selective modulator of sphingosine-1-phosphate (S1P) receptors 1 and 5, has demonstrated efficacy in relapsing-remitting multiple sclerosis (RMS) in Phase 2 and 3 studies. At a dose of 0.92...…
View Post 3 min This content is machine translated Brain atrophy and MS Brain atrophy correlates with disability progression in MS Brain atrophy in MS patients, particularly in the thalamus, correlates strongly with long-term physical disability and cognitive deficits. A long-term analysis of the phase 3 studies RADIANCE/SUNBEAM and the open-label...…
View Post 7 min This content is machine translated ECTRIMS/ACTRIMS in Paris MS in children – Does the same apply to therapy as in adults? At the ECTRIMS/ACTRIMS Congress, for once the pediatric population came into focus. Fingolimod was shown to be effective here as well. But the benefits don’t come “free.”
